Atb Cap Markets Issues Pessimistic Forecast for OGI Earnings

Key Points

• Analysts at Atb Cap Markets have revised down their FY2028 earnings per share estimate for Organigram Global Inc. from $0.11 to $0.10, while the consensus expectation remains at ($0.19) per share.
• Organigram's recent quarterly earnings report showed a loss of ($0.03) EPS, missing analysts' expectations; the company also reported revenues of $50.49 million, which fell short of the projected $68.04 million.
• The stock price of Organigram has seen fluctuations, recently trading at $1.52, with a market capitalization of $203.06 million and shares owned by institutional investors accounting for 34.63% of total shares.

Organigram Global Inc. (NASDAQ:OGI - Free Report) - Stock analysts at Atb Cap Markets cut their FY2028 earnings per share estimates for Organigram Global in a research report issued to clients and investors on Wednesday, August 13th. Atb Cap Markets analyst F. Gomes now anticipates that the company will earn $0.10 per share for the year, down from their previous estimate of $0.11. The consensus estimate for Organigram Global's current full-year earnings is ($0.19) per share.

Organigram Global Price Performance

Shares of NASDAQ OGI traded down $0.05 during trading on Friday, reaching $1.52. 200,088 shares of the stock traded hands, compared to its average volume of 722,617. Organigram Global has a 52-week low of $0.85 and a 52-week high of $2.08. The company has a 50-day moving average of $1.42 and a 200-day moving average of $1.27. The stock has a market capitalization of $203.06 million, a P/E ratio of 30.31 and a beta of 1.45.

Organigram Global (NASDAQ:OGI - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). Organigram Global had a net margin of 2.86% and a negative return on equity of 8.49%. The firm had revenue of $50.49 million for the quarter, compared to analysts' expectations of $68.04 million.

Hedge Funds Weigh In On Organigram Global

A number of institutional investors have recently added to or reduced their stakes in OGI. Two Sigma Securities LLC bought a new position in shares of Organigram Global during the 4th quarter valued at about $26,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Organigram Global during the 1st quarter valued at about $30,000. Oxford Asset Management LLP bought a new position in shares of Organigram Global during the 4th quarter valued at about $50,000. Cidel Asset Management Inc. increased its position in shares of Organigram Global by 112.3% during the 2nd quarter. Cidel Asset Management Inc. now owns 37,103 shares of the company's stock valued at $50,000 after purchasing an additional 19,627 shares during the last quarter. Finally, Clear Harbor Asset Management LLC bought a new position in shares of Organigram Global during the 2nd quarter valued at about $54,000. 34.63% of the stock is currently owned by institutional investors.

Organigram Global Company Profile

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.